This approach combines PDPN expression levels with radiomics data of high-grade glioma patients, incorporating the gradient boosting machine model into radiomic feature analysis and demonstrating significant correlations with both tumor heterogeneity and PDPN expression levels. The gene discussed is PDPN; the disease is glioma.